Personal information

United States

Activities

Employment (3)

Memorial Sloan Kettering Cancer Center: New York, NY, US

2024-09-16 to present | Research Project Associate (Cto solid tumor gu p)
Employment
Source: check_circle
Memorial Sloan Kettering Cancer Center

Columbia University Irving Medical Center: New York, US

2022-05-09 to 2024-09-13 | Staff Associate II (Department of Radiation Oncology)
Employment
Source: Self-asserted source
Patrick McCann

Columbia University Irving Medical Center: New York, US

2021-07-19 to 2022-05-06 | Clinical Research Coordinator (Clinical Protocol and Data Management)
Employment
Source: Self-asserted source
Patrick McCann

Works (8)

Abstract CT137: Efficacy and immunological outcomes of non-fucosylated anti-CTLA-4 (BMS-986218) + degarelix acetate vs. degarelix acetate alone in men with high-risk localized prostate cancer (Neo-Red-P)

Cancer Research
2024-04-05 | Journal article
Part of ISSN: 1538-7445
Contributors: Patrick J. McCann; Casey R. Ager; Aleksandar Z. Obradovic; Matthew G. Chaimowitz; Samuel Pan; Caroline J. Laplaca; Parin Shah; Renu K. Virk; Christopher B. Anderson; Catherine S. Spina et al.
Source: Self-asserted source
Patrick McCann

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response.

Journal for immunotherapy of cancer
2023-09-01 | Journal article
Contributors: Casey Ager; Zhang M; Chaimowitz M; Bansal S; Tagore S; Obradovic A; Collin Jugler; Rogava M; Melms JC; McCann P et al.
Source: Self-asserted source
Patrick McCann

Abstract B032: Combined A2AR and PARP inhibition in homologous recombination deficient (HRD) castrate-resistant prostate cancer (CRPC)

Cancer Research
2023-06-02 | Journal article
Part of ISSN: 1538-7445
Contributors: Patrick J. McCann; Wendy Mao; Matthew Chaimowitz; Erika Houthys; Reece Marillier; Shruti Bansal; Julia An; Jason A. Piersaint; Namita Sen; Charles G. Drake et al.
Source: Self-asserted source
Patrick McCann

Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators.

Cancer cell
2023-04-27 | Journal article
Contributors: Aleksandar Obradovic; Ager C; Turunen M; Nirschl T; Khosravi-Maharlooei M; Iuga A; Jackson CM; Yegnasubramanian S; Tomassoni L; Fernandez EC et al.
Source: Self-asserted source
Patrick McCann

Abstract 1101: Combination therapy to overcome radiotherapy induced immunosuppression and improve tumor control

Cancer Research
2023-04-04 | Journal article
Part of ISSN: 1538-7445
Contributors: Shruti Bansal; Matthew Chaimowitz; Julia Ann; Patrick McCann; Jason Piersaint; Claudia Aiello; Namita Sen; Julia Kogan; Catherine Spina
Source: Self-asserted source
Patrick McCann

Urokinase-type plasminogen activator promotes N-cadherin-mediated synaptic recovery in the ischemic brain.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
2021-03-24 | Journal article
Contributors: Diaz A; Merino P; McCann P; Yepes MA; Quiceno LG; Torre E; Amelia Tomkins; Zhang X; Hales CM; Tong FC et al.
Source: Self-asserted source
Patrick McCann

Urokinase-type plasminogen activator protects cerebral cortical neurons from soluble Aβ-induced synaptic damage.

The Journal of neuroscience : the official journal of the Society for Neuroscience
2020-04-24 | Journal article
Contributors: Ariel Díaz; Merino P; Guo JD; Yepes MA; McCann P; Tapasya Katta; Tong EM; Torre E; SRIKANT RANGARAJU; Manuel Yepes
Source: Self-asserted source
Patrick McCann

Tissue-type plasminogen activator regulates p35-mediated Cdk5 activation in the postsynaptic terminal.

Journal of cell science
2019-02-28 | Journal article
Contributors: Ariel Díaz; Jeanneret V; Paola Merino; McCann P; Manuel Yepes
Source: Self-asserted source
Patrick McCann